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Abstract 
Background: Parkinson’s disease (PD) and schizophrenia (SCZ) are heritable brain disorders that both 
involve dysregulation of the dopaminergic system. Epidemiological studies have reported potential 
comorbidity between the disorders, and movement disturbances are common in SCZ patients before 
treatment with antipsychotic drugs. Despite this, little is known about shared genetic etiology 
between the disorders.   
Methods: We analyzed recent large genome-wide associations studies (GWAS) on SCZ (n=77,096) 
and PD (n=417,508) using a conditional/conjunctional false discovery rate (FDR) approach to 
evaluate overlap in common genetic variants and improve statistical power for genetic discovery. 
Using a variety of biological resources, we functionally characterized the identified genomic loci.  
Results: We observed genetic enrichment in PD conditional on associations with SCZ, and vice versa, 
indicating polygenic overlap. We then leveraged this cross-trait enrichment using conditional FDR 
analysis and identified nine novel PD risk loci and one novel SCZ locus at conditional FDR<0.01. 
Further, we identified nine genomic loci jointly associated with PD and SCZ at conjunctional 
FDR<0.05. There was an even distribution of antagonistic and agonistic effect directions among the 
shared loci, in line with the insignificant genetic correlation between the disorders. 65 out of 67  
genes mapped to the shared loci are expressed in the human brain and show cell-type specific 
expression profiles.  
Conclusions: Altogether, the study increases the understanding of the genetic architectures 
underlying SCZ and PD, indicating that common molecular genetic mechanisms may contribute to 
overlapping pathophysiological and clinical features between the disorders. 
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Introduction  
Parkinson’s disease (PD) and schizophrenia (SCZ) are severe brain disorders with complex etiologies 
that involve multiple genetic and environmental factors. While SCZ is considered a 
neurodevelopmental disorder with typical onset in early adulthood, PD is a neurodegenerative 
disorder with most cases occurring after the age of 60. PD is characterized by degeneration of 
dopaminergic neurons in the substantia nigra, manifesting clinically with motor symptoms such as 
bradykinesia, tremor and rigidity (1). Current treatment strategies in PD largely aim to increase 
dopaminergic activity (1). SCZ, on the other hand, is characterized by psychotic symptoms such as 
hallucinations, delusions and thought distortions, in addition to mood symptoms, loss of motivation 
and cognitive dysfunction (2). Despite their distinguishable clinical manifestations and different ages 
at onset, SCZ and PD share some disease characteristics, most notably abnormalities of the 
dopaminergic system (1, 2). Whereas PD is associated with dopaminergic deficiency (1), the 
psychotic symptoms of SCZ are associated with increased dopaminergic signaling in the striatum (2, 
3). In fact, almost all effective antipsychotic drugs are antagonists of dopamine D2 receptors, with 
parkinsonian symptoms representing one of the most common adverse effects (4). Moreover, the 
non-psychotic symptoms of SCZ have been linked to lower dopaminergic transmission in the 
mesocortical pathway (3). Further, symptoms associated with SCZ, like hallucinations, depression 
and cognitive dysfunction, are common in patients with PD (5, 6), and may even occur in drug-naïve 
PD patients (5, 7). Intriguingly, meta-analyses have reported an increased prevalence of movement 
disturbances such as dyskinesia and parkinsonism among antipsychotic-naïve patients with SCZ and 
their healthy first-degree relatives (8, 9), suggesting that genetic risk may play a role. In line with 
this, a recent large population-based family cohort study found that first-degree relatives of patients 
with PD were more likely to develop SCZ (10). 
Additionally, two epidemiological studies reported higher rates of PD among patients with SCZ (11, 
12), although the findings from these two studies may have been biased from drug-induced 
parkinsonism. However, despite the clinical and epidemiological associations between SCZ and PD, 
little is known about shared genetic etiology between the disorders.   
The genetic architectures of both PD (13-15) and SCZ (16) are highly polygenic, with many genetic 
variants with small effects contributing to disease risk. Recent large GWAS on PD (13-15, 17) have 
identified 92 genome-wide significant loci, and more than hundred genome-wide significant loci are 
linked to SCZ (16, 18). Intriguingly, five genome-wide significant loci have been jointly associated 
with SCZ (16) and PD in recent GWAS (13, 15-17). Moreover, two systematic investigations of GWAS 
summary data implicated loci shared between SCZ and PD within NT5C2 (19) and SLC39A8 (20). 
Notably, both PD (21) and SCZ (22) are also associated with the 22q11.2 deletion syndrome. Despite 
the overlapping genetic associations between SCZ and PD, genetic studies have reported no 
genome-wide correlation between the disorders (23). A significant genome-wide correlation, 
however, requires consistent effect directions among the overlapping variants between two 
phenotypes (24), which is not necessarily the case despite polygenic overlap. Indeed, increasing 
evidence indicates that there is a mixed pattern of allelic effect directions among variants shared 
between a number of complex human traits and disorders (25-33), warranting more detailed 
analyses to disentangle the genetic relationship between complex phenotypes. In the present study 
we aimed to further investigate the shared genetic basis between SCZ and PD, and applied the 
conditional false discovery rate (condFDR) approach (34) to analyze recent large non-overlapping 
GWAS on PD (n=417,508) (13, 15) and SCZ (n=77,096) (16). The condFDR approach builds on an 
empirical Bayesian statistical framework, and increases power to detect shared loci by leveraging the 
combined power of two GWAS (34). We have in recent years used this approach to identify shared 
genetic influences between a number of complex human traits and disorders (25, 27, 30, 35-42). 
Methods and Materials  
GWAS data  
We obtained GWAS results in the form of summary statistics (p-values and effect sizes) (13, 15, 16). 
All participants were of European ancestry. First, we meta-analyzed two independent GWAS on PD 
(13, 15): a 23andMe cohort on 6,476 cases and 302,042 controls described in Chang et al (2017) (13) 
and a PDGene cohort on 13,708 cases and 95,282 controls described in Nalls et al (2014) (15). A 
similar meta-analysis was conducted in the Chang et al (2017) study (13), but was restricted to the 
10,000 most significant single-nucleotide polymorphisms (SNPs) from the PDGene study (15). For our 
meta-analysis, however, we utilized the complete summary statistics data from both the PDGene 
study (7,799,579 variants) (15) and the 23andMe cohort (12,896,220 variants) (13). We combined 
the association statistics for the meta-analysis of the 23andMe (13) and PDGene (15) cohorts using 
an inverse-variance weighted method as implemented in METAL (43). In the 23andMe cohort, cases 
and controls were designated on the basis of web-based self-report surveys on 23andMe research 
participants (13). The PDGene GWAS meta-analyzed 15 studies using different criteria for 
case/control ascertainment (15). Data on SCZ were acquired from the Psychiatric Genomics 
Consortium (PGC) (16), consisting of 46 case control samples (33,640 cases with SCZ or 
schizoaffective disorder and 43,456 controls) and 3 family-based association studies (1,235 parent 
affected-offspring trios) (16) (15,358,497 variants). We also included GWAS summary statistics on 
four disorders as negative controls, namely attention-deficit hyperactivity disorder (ADHD; 19,099 
cases and 34,194 controls) (44), autism spectrum disorder (ASD; 8,381 cases and 27,969 controls) 
(45), haemorrhoids (12,102 cases, 349,092 controls) and prostate cancer (25,074 cases and 24,272 
controls) (46). All GWAS investigated in the present study were approved by the relevant ethics 
committees, and informed consent was obtained from all participants. The Norwegian Institutional 
Review Board for the South-East Norway Region has evaluated the current protocol and found that 
no additional institutional review board approval was needed because no individual data were used. 
For details, see Supplemental Methods.  
condFDR analysis  
The condFDR method builds on an empirical Bayesian statistical framework (47) and capitalizes on 
the inherent power in combining two GWAS to improve discovery of genetic variants (34). First, we 
constructed conditional Q-Q plots to provide a visual pattern of overlap in SNP associations, i.e. 
“cross-trait enrichment”. Note that cross-trait enrichment indicates shared genomic loci between 
the phenotypes, which could reflect both shared or separate causal variants (48). The conditional Q-
Q plots compare the association with a primary trait across all SNPs and within SNPs strata 
determined by their association with the secondary trait (34, 49). To improve SNP discovery in SCZ 
and PD, the condFDR statistical framework (34, 49) re-ranks the test-statistics of a primary 
phenotype based on the strength of the association with a secondary phenotype (34, 49). Inverting 
the roles of primary and secondary phenotypes gives the inverse condFDR value. The conjunctional 
FDR (conjFDR), defined in turn as the maximum of the two condFDR values, provides a conservative 
estimate of the FDR for association with both phenotypes. In line with the prior literature (25, 30, 35, 
37-42), the significance threshold for shared loci was conjFDR<0.05 and for conditional loci 
condFDR<0.01. We excluded SNPs around the extended MHC region, chromosome 8p23.1 and the 
gene MAPT (genome build 19 locations chr6:25119106–33854733, chr8:7200000–12500000 and 
chr17:40000000–47000000, respectively) before fitting the FDR model, given that their intricate 
regional LD may bias FDR estimation (50). All p-values were corrected for inflation using a genomic 
inflation control procedure (40). For methodological details of the condFDR approach, see 
Supplemental Methods or the review by Smeland and colleagues (2019) (34).  
Genomic loci definition  
We defined independent genomic loci according to the FUMA (51) protocol. FUMA is an online 
platform for functional mapping of genetic variants (http://fuma.ctglab.nl/) (51). First, we identified 
independent significant SNPs as SNPs that were independent from each other at r2<0.6 and that 
reached a condFDR<0.01 or conjFDR<0.05, in the respective condFDR and conjFDR analyses. A 
subset of these in approximate linkage equilibrium with each other at r2<0.1 were then selected as 
lead SNPs. To define distinct genomic loci, we merged all loci which were less than 250kb apart 
selecting a SNP with the most significant p-value as a lead SNP of the merged locus. The borders of 
the genomic loci were defined by identifying all SNPs (candidate SNPs) in LD (r2≥0.6) with one of the 
independent significant SNPs in the locus. Overlapping signals within complex LD regions were 
represented by one independent lead SNP only. All LD information was calculated from the 1000 
Genomes Project European-ancestry haplotype reference panel (52). We evaluated the directional 
effects of the loci shared between SCZ and PD by comparing their z-scores and odds ratios.  
Functional annotation  
Using FUMA (51), we functionally annotated all candidate SNPs in the genomic loci having an LD 
r2≧0.6 with one of the independent significant SNPs and having a condFDR or conjFDR value <0.10. 
SNPs were annotated with Combined Annotation Dependent Depletion (CADD) (53) scores, which 
predict how deleterious the SNP effect is on protein structure/function, RegulomeDB (54) scores, 
which predict likelihood of regulatory functionality, and chromatin states, which predict 
transcription/regulatory effects from chromatin states at the SNP locus (55, 56). Using FUMA (51), 
we linked candidate SNPs to genes using either of three gene-mapping strategies: 1) positional 
mapping to align SNPs to genes based on their physical proximity, 2) expression quantitative trait 
locus (eQTL) mapping to match cis-eQTL SNPs to genes whose expression is associated with allelic 
variation at the SNP level, and 3) chromatin interaction mapping to link SNPs to genes based on 
three-dimensional DNA–DNA interactions between each SNP’s genomic region and nearby or distant 
genes. Next, we determined the expression in the adult human brain of the identified genes using 
Genotype-Tissue Expression (GTEx) (57) data and we performed a gene-set analysis using FUMA. 
Finally, we used a publicly available RNA-sequencing transcriptome and splicing database (58) to 
determine the cell-specific expression within the human cerebral cortex of the genes implicated by 
the shared loci. The six cell types surveyed were neurons, fetal and mature astrocytes, 
oligodendrocytes, microglia/macrophages, and endothelial cells (58). For details, see Supplemental 
Methods. 
Results  
We observed enrichment in SCZ SNPs as a function of the significance of associations with PD (Figure 
1A). This indicates polygenic overlap between the disorders. The reverse conditional Q-Q plots 
demonstrate consistent enrichment in PD given associations with SCZ (Figure 1B). We also observed 
cross-trait enrichment between SCZ and the psychiatric disorders ADHD and ASD, but not with 
haemorrhoids or prostate cancer (Supplemental Figures 1-4). In contrast, we did not observe cross-
trait enrichment between PD and any of the four control disorders, despite polygenic signal. The 
results indicate specificity for the cross-trait enrichment between PD and SCZ. However, we cannot 
exclude the possibility that the negative findings are due to inadequate statistical power, and that 
future larger GWAS may show some overlap.  
To increase statistical power for genetic discovery, we leveraged the cross-trait enrichment between 
SCZ and PD using condFDR analysis (34) and re-ranked PD SNPs conditionally on their association 
with SCZ, and vice versa. At condFDR<0.01, we identified 53 loci associated with PD conditional on 
SCZ (Supplemental Table 1). Of these, 33 loci had been identified in the original PD GWAS (13, 15), 
two were identified in subsequent GWAS analyses (the NUCKS1 (41) and SLC39A8 (20) loci), while 
nine reached genome-wide significance in a recent larger PD GWAS (17). In total, we identified nine 
novel PD risk loci (Table 1), implicating 54 genes (Supplemental Table 3). Two of the lead SNPs in the 
novel PD risk loci, rs56379273 and rs181870458, were only present in the 23andMe dataset (13), but 
not the PDGene dataset (15), indicating that these associations may have lower confidence. 
Furthermore, we identified 119 loci associated with SCZ at condFDR<0.01 (Supplemental Table 4). 
Twenty-three of these loci were not identified in the original SCZ GWAS (16). However, all but one 
have been associated with SCZ in subsequent GWAS analyses (18, 25, 27, 30, 59, 60). The sole novel 
SCZ locus was detected near pseudogene RNU6-183P with rs9293740 as lead SNP (chromosome 
5:77612246; p-value SCZ = 5.81 x  
10-6, p-value PD = 9.27 x 10-4, condFDR = 8.16 x 10-3; Table 2). Five protein-coding genes 
were also mapped to this locus, with AP3B1 as nearest gene (Supplemental Table 6). Supplemental 
Figures 5-6 present the condFDR Manhattan plots for PD and SCZ, showing all SNPs with a 
condFDR<0.01 within an LD block in relation to their chromosomal location.  
Nine distinct genomic loci were jointly associated with SCZ and PD at conjFDR<0.05 (Table 3). All of 
these loci have previously been associated with SCZ (16, 18). Five of the shared loci already reached 
genome-wide significance in the PD GWAS presently analyzed (13, 15), while the CLCN3 locus was 
identified in the recent larger PD GWAS (17), and the NT5C2 (19) and SLC39A8 (20) loci have been 
associated with PD in other GWAS investigations. Altogether, we identified two novel PD risk loci 
among the shared loci, at RERE (lead SNP rs302714, chromosome 1:8486131, p-value SCZ = 2.37 x 
10-8, p-value PD = 4.23 x 10-6, conjFDR = 3.16 x 10-3), and at ZDHHC2 (lead SNP rs4921739, 
chromosome 8:17029657, p-value SCZ = 1.24 x 10-6, p-value PD = 6.20 x 10-6, conjFDR=4.27 x 10-3). 
As denoted by the sign of the effect sizes, five of the shared loci have consistent effect directions in 
SCZ and PD, indicating that the respective risk alleles are linked to higher susceptibility to both SCZ 
and PD (Table 3). Two of the nine shared loci were located in regions with complex LD, specifically 
the extended MHC region (locus 4, lead SNP rs9468195) and chromosomal region 8p23.1 (locus 5, 
lead SNP rs2979160). Both of these loci have previously been associated with SCZ and PD at the 
genome-wide significance level (13, 14, 16). Due to their extensive LD, these regions span large 
numbers of genes (61, 62), and we consider these conjunctional hits as to reflect the involvement of 
the extended MHC and 8p23.1 regions in both disorders rather than any specific gene. Note that we 
excluded SNPs in these LD regions before fitting the condFDR model to avoid inflation of the FDR 
estimation.   
Functional annotation (51) of all SNPs having a conjFDR value<0.10 in the loci shared between SCZ 
and PD (n=551) demonstrated that these were mostly intronic and intergenic, while 1.3% were 
exonic (Supplemental Table 7). To visualize the genomic distribution of the shared variants and their 
nearest genes, we constructed a ‘conjFDR Manhattan plot’ where all SNPs without pruning are 
shown, and the independent significant lead SNPs are encircled in black (Figure 2). After excluding 
the MHC and 8p23.1 loci, we applied FUMA (51) to link the 97 candidate SNPs in the seven shared 
loci to 67 protein-coding genes (Supplemental Table 8).Positional mapping aligned the SNPs to 11 
genes, cis-eQTL mapping implicated 51 genes, and chromatin interaction mapping implicated 27 
genes. Three genes were implicated by all three gene-mapping procedures, specifically RERE and 
SLC45A1 at chromosome 1p36.23 and IGSF9B at chromosome 11q25, giving a higher credibility for 
the link between these genes and loci. Notably, seven genes were mapped to SNPs with cis-eQTL 
associations in separate eQTL databases on human brain tissue (57, 63-65), specifically RERE, 
SLC45A1, IGSF9B, VPS37A, MTMR7, CNNM2 and NT5C2. The gene mapping strategy only implicated 
29 genes when restricting the eQTL associations and chromatin interactions to those detected in 
human brain tissue. Using GTEx data (57), we show that 65 of the genes mapped to the shared loci, 
but not CA6 and SPATA19, are expressed in the human brain (Supplemental Figure 7). Moreover, we 
demonstrate cell-type specific expression profiles in the major cell types in the human cerebral 
cortex for the 65 brain-expressed genes (Supplemental Figure 8). A gene-set analysis identified no 
biological process significantly associated with the 67 genes. 
Discussion 
In the present study, we investigated non-overlapping GWAS summary statistics on PD (13, 15) and 
SCZ (16) to increase insights into their shared genetic etiology. First, we constructed conditional Q-Q 
plots, which indicate polygenic overlap between SCZ and PD (Figure 1), supporting prior genetic 
findings (13, 15-17, 19, 20). Next, we leveraged the cross-trait enrichment using condFDR analysis 
and identified nine novel PD loci (Table 1), one novel SCZ locus (Table 2), and nine genomic loci 
jointly associated with SCZ and PD (Table 3), two of which are novel shared loci. The demonstration 
of polygenic overlap between SCZ and PD, including both agonistic and antagonistic SNP effects, is 
likely to generate novel hypotheses into their relationship and may inform clinical practices. The 
findings indicate that in some patients, genetic variants shared by SCZ and PD may possibly 
contribute to overlapping clinical and pathophysiological features between the disorders, for 
example dyskinesia and parkinsonism in antipsychotic-naïve SCZ patients (8, 9). However, the even 
distribution of directional effects among the shared loci does not explain the potential comorbidity 
between SCZ and PD as suggested by epidemiological studies (10-12), indicating that environmental 
factors or rare genetic variants may play a role. Furthermore, the results suggest that in order to 
develop valid genetic prediction tools identifying patients at higher risk of comorbid SCZ and PD 
symptomatology, these tools would need to focus on the subset of the overlapping variants with 
agonistic effects, in addition to the risk variants not shared by the disorders. Such tools are currently 
lacking in the clinic. The findings may also have implications for clinical trials in PD and SCZ, by 
supporting the collection and sequencing of DNA for better risk stratification.   
Although much of the genetic architectures underlying SCZ and PD remain to be identified, seven 
genomic loci are already found to be shared between the disorders (13, 15- 17, 19, 20). Here, we 
provide additional support for these overlapping associations and identify two novel shared loci, 
yielding a total number of nine loci shared between SCZ and PD (Table 3; Figure 2). Notably, a recent 
large genetic study (23) examined shared heritability between multiple brain disorders using LD 
score regression and reported no genetic correlation between SCZ and PD (23). This result mirrored 
the non-significant correlations between other psychiatric and neurological disorders (23), which has 
been interpreted to signify that psychiatric and neurological disorders have distinct non-overlapping 
genetic etiologies (23). However, genetic correlations can only capture consistent allelic effect 
directions among shared variants, and are agnostic about mixed patterns of directional effects (24). 
Among the nine shared loci identified here, the allelic effect directions were consistent at five loci 
(Table 3). This balanced mixture of directional effects complies with the non-significant genetic 
correlation between SCZ and PD (23), and indicates that agonistic and antagonistic overlapping 
molecular genetic mechanisms may be involved in SCZ and PD pathophysiology. Note that it is 
possible that our finding of polygenic overlap between SCZ and PD may have been biased from 
misdiagnosis in the separate GWAS investigated (13, 15, 16), i.e., that parkinsonian side effects in 
SCZ patients were misclassified as symptoms of PD, or that drug-induced psychosis in PD patients 
was misdiagnosed as SCZ. Although we are unable to control for this possible bias, the number of 
such cases is likely to have been very small, and this potential occurrence would be unable to explain 
the identification of shared variants with opposite effect directions in SCZ and PD.  
Using the condFDR approach to improve genetic discovery, we identified 23 SCZ loci and 20 PD loci 
at condFDR<0.01 not identified in the original GWAS analyzed (13, 15, 16) (Supplemental Tables 1 
and 4). However, among these, as many as 22 of the SCZ loci (18, 25, 27, 30, 59, 60) and eleven of 
the PD loci (17, 20, 41) have been associated with the disorders in subsequent GWAS analyses, 
supporting their role in SCZ and PD etiology. These results demonstrate the validity of the condFDR 
approach to increase the yield of existing GWAS. Among the candidate SNPs in the nine novel PD risk 
loci, two of the SNPs, rs2278973 (chromosome 9:141016262) and rs56379273 (chromosome 
21:45826486), are nonsynonymous exonic variants within genes CACNA1B and TRPM2, respectively 
(Supplemental Table 2). These SNPs were also the most strongly associated SNPs in these loci. 
Nonsynonymous exonic variants are more likely to disrupt protein function by altering the amino 
acid sequence of the protein. CACNA1B encodes a voltage-dependent calcium channel subunit 
widely expressed in the nervous system, which regulates neurotransmission (66). A rare CACNA1B 
mutation has been implicated in SCZ (67). Another CACNA1B mutation has been associated with a 
myoclonus-dystonia syndrome (68), but the evidence is inconsistent (69). The TRPM2 variant had a 
CADD-score of 17.7, further suggesting deleteriousness (53) (Supplemental Table 2). TRPM2 encodes 
a member of the melastin-related transient receptor potential (TRPM) family of cation channels, 
which regulates ion homeostasis and membrane potential in various cell types (70). TRPM2 has been 
linked to the regulation of GABAergic activity in the substantia nigra (71), and apoptosis in 
dopaminergic neurons after exposure to neurotoxins (72). Note that the locus at TRPM2 was also 
mapped to two other protein-coding genes, PFKL and AP001579.1, through eQTL associations 
(Supplemental Table 3).   
The novel PD risk loci at RERE and ZDHHC2 were also found to be shared between PD and SCZ at 
conjFDR<0.05 (Table 3). The RERE locus reached genome-wide significance in the original SCZ GWAS 
(16), while the ZDHHC2 locus reached genome-wide significance in a recent transancestry SCZ GWAS 
(18) that also included the original PGC SCZ GWAS dataset (16). At the RERE locus, the SCZ risk allele 
was associated with lower PD risk (Table 3). In addition to being the nearest gene to most of the 
candidate SNPs in this locus, RERE was implicated through eQTL associations in multiple tissues 
including the brain, and through chromatin interactions (Supplemental Table 8). Nine other genes 
were also mapped to this locus, but with lower confidence. RERE encodes a nuclear receptor 
coregulator that regulates retinoic acid signaling in several tissues during development (73). 
Deleterious variants within RERE have been linked to neurodevelopmental disease (74), and 
common RERE variants have been implicated in major depression (75). The SCZ and PD risk alleles 
were agonistic at the ZDHHC2 locus (Table 3). ZDHHC2 was mapped to this locus as both the nearest 
gene and through eQTL functionality in different tissues, including the cerebellum (Supplemental 
Table 8). Five other genes were also linked to this locus, but with lower confidence. ZDHHC2 encodes 
a palmitoyl transferase, which regulates diverse protein activities (76), including organization of the 
postsynaptic density (77). ZDHHC2 was identified as a key protective gene regulator in a mouse 
model of PD, which prevented dopaminergic cell death in the substantia nigra pars compacta (78). 
Additionally, transcriptional activity of ZDHHC2 was decreased in the substantia nigra of patients 
with incipient PD (78). Of note, as previously shown (20), there are strong antagonistic effects on SCZ 
and PD associated with rs13107325 (Table 3), a highly pleiotropic missense variant within SLC39A8, 
which encodes a metal ion transporter (79). The minor T allele of rs13107325, which is linked to 
higher SCZ risk and lower PD risk (20), is also associated with poorer cognitive function (30) and 
larger gray matter volume in the putamen (80), a brain structure part of the nigrostriatal 
dopaminergic pathway (81). Our functional analysis further demonstrated that 65 out of the 67 
protein-coding genes mapped to the shared loci are expressed in the human brain (Supplemental 
Figure 7), in which they present distinct expression profiles across the major cell types (58) 
(Supplemental Figure 8).   
In conclusion, we corroborate prior genetic findings (13, 15-17, 19, 20) by demonstrating polygenic 
overlap between SCZ and PD and highlighting nine shared loci with a mixed pattern of directional 
effects (Table 3). Further studies are needed to clarify the distinct causal variants underlying the 
shared genomic associations detected here, which could arise from both shared or separate causal 
variants (48), and to determine whether the variants influence SCZ and PD pathobiology through 
common intermediary phenotypes or more basic neurobiological mechanisms, such as interfering 
with dopaminergic function. The study demonstrates the utility of the condFDR statistical framework 
to increase genetic discovery and uncover polygenic overlap between complex phenotypes despite 
the absence of genetic correlation (34, 49), which may be useful for elucidating genetic overlap 
between other psychiatric and neurological disorders.   
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